مباشر

FierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target FierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer FierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapy FierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia FierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reports Lonza NewsSimulations Plus (SLP) Partners with FDA and Lonza for Drug Perf - GuruFocus Lonza NewsSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks fo - PharmiWeb.com Lonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com BioWorldJapanese researchers report new μ-opioid receptor antagonists BioWorldIncyte discloses new TYK2 and/or JAK1 inhibitors BioWorldInsilico Medicine divulges new NLRP3 inflammasome inhibitors BioWorldNeolaia synthesizes new CD38 inhibitors

Cell ٢٥ نوفمبر ٢٠٢٥

Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy

Publication date: Available online 19 November 2025Source: CellAuthor(s): Michelle von Locquenghien, Pascale Zwicky, Ken Xie, Diego Adhemar Jaitin, Fadi Sheban,...

Publication date: Available online 19 November 2025Source: CellAuthor(s): Michelle von Locquenghien, Pascale Zwicky, Ken Xie, Diego Adhemar Jaitin, Fadi Sheban, Adam Yalin, Florian Uhlitz, Chamutal Gur, Reut Sharet Eshed, Eyal David, Kfir Mazuz, Caroline Jennings Marin, Ankita Sankar, Devin Mediratta, Roberto Avellino, Assaf Weiner, Ido Amit